Results 241 to 250 of about 27,503 (257)

Dipeptidyl‐Peptidase‐4 Inhibitor, Alogliptin, Attenuates Arterial Inflammation and Neointimal Formation After Injury in Low‐Density Lipoprotein (LDL) Receptor‐Deficient Mice

Journal of the American Heart Association, 2015
Kazunori Shimada, Kikuo Isoda
exaly  

Gastrointestinal Adverse Events of Dipeptidyl Peptidase 4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-analysis

Clinical Therapeutics, 2017
Linong Ji, Yang Xu, Siyan Zhan
exaly  

Ameliorating effect of the novel dipeptidyl peptidase-4 inhibitor teneligliptin on psoriasis: A report of two cases

Journal of Dermatology, 2015
Hiroshi Nagai, Susumu Fujiwara
exaly  

Synthesis of a Dipeptidyl Peptidase-4 Inhibitor

Synfacts, 2019
openaire   +1 more source

Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial?

Diabetes and Vascular Disease Research, 2019
Nordin Mj Hanssen
exaly  

Synthesis of a Dipeptidyl Peptidase 4 Inhibitor

Synfacts, 2009
openaire   +1 more source

Alogliptin: A New Dipeptidyl Peptidase-4 Inhibitor for Type 2 Diabetes Mellitus

Annals of Pharmacotherapy, 2013
Courtney I Jarvis
exaly  

Dipeptidyl peptidase IV inhibitors as new therapeutic agents for the treatment of Type 2 diabetes

Expert Opinion on Therapeutic Patents, 2003
Koen Augustyns, Pieter Van der Veken, Achiel Haemers   +2 more
exaly  

Dipeptidyl peptidase-4 inhibitors/metformin

Reactions Weekly, 2018
openaire   +1 more source

Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials

Current Medical Research and Opinion, 2011
Matteo Monami, Edoardo Mannucci, Ilaria Dicembrini   +2 more
exaly